U.S.-based pharmaceutical giant Eli Lilly has officially launched its widely popular drug, Mounjaro, in India.
Containing the active ingredient tirzepatide, the medication is designed for managing type 2 diabetes, blood sugar levels, and weight, offering a new hope for millions of Indians struggling with obesity and diabetes.
Mounjaro, a once-weekly injectable prescription drug, has been approved by India’s Central Drugs Standard Control Organisation (CDSCO). It works by activating hormones GIP and GLP-1 to regulate blood sugar and appetite, making it an effective addition to a healthy diet and exercise regimen.
Eli Lilly has emphasized Mounjaro’s target audience includes:
- Adults with obesity (BMI of 30 or more),
- Overweight adults with related health concerns (BMI of 27 or more),
- Adults managing type 2 diabetes.
Clinical Evidence: Global trials, including the SURMOUNT-1 and SURPASS studies, have demonstrated impressive results. In the SURMOUNT-1 study, participants using Mounjaro alongside lifestyle changes achieved average weight reductions of up to 21.8 kg over 72 weeks. Meanwhile, the SURPASS trial highlighted the drug’s efficacy in lowering blood sugar levels by up to 2.4% within 40 weeks.
Addressing India’s Health Crisis: With approximately 101 million Indians living with diabetes and 100 million affected by obesity, Mounjaro’s entry is considered a significant milestone in combating these pressing health challenges. “Our goal is to bring innovative medicines to India and improve awareness about managing diabetes and obesity,” said Winselow Tucker, President of Lilly India.
Doctors and health experts view this launch as a vital step toward providing effective, long-term solutions for patients grappling with these life-altering conditions.
This development underscores Eli Lilly’s commitment to healthcare innovation and improving patient outcomes in India.
